Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Advaxis reports update on phase II study of ADXS-HPV

Jan. 29, 2015

FDA clears IND for phase I study of ADXS-HER2

Jan. 23, 2015

Phase I/II results of isactuzumab govitecan in gastrointestinal cancer patients

Jan. 22, 2015

BioInvent's BI-1206 to enter collaborative phase I/II trial

Jan. 21, 2015

Safety and dosing data presented for a novel gastric cancer vaccine

Jan. 19, 2015

OncoMed enrolls first biomarker-selected patient in anti-Notch 1 expansion trial

Jan. 16, 2015

Promising results presented for chimeric antigen receptors in B-cell cancer treatment

Jan. 15, 2015

Precision Biologics discloses interim survival data for NPC-1C in metastatic colorectal cancer

Jan. 15, 2015

EMA grants positive opinion for orphan drug status for enadenotucirev

Jan. 14, 2015

Asana BioSciences researchers prepare immunofusion molecules for cancer

Jan. 14, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...